{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:30:15Z","timestamp":1794241815956,"version":"4.9.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001125","name":"GAVI Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001125","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.vaccine.2021.04.025","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T19:06:20Z","timestamp":1620155180000},"page":"A2-A9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"S1","title":["National introduction of human papillomavirus (HPV) vaccine in Tanzania: Programmatic decision-making and implementation"],"prefix":"10.1016","volume":"40","author":[{"given":"Alex","family":"Mphuru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anyie J.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furaha","family":"Kyesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Mwengee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fikiri","family":"Mazige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Nshunju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berrington","family":"Shayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Rose","family":"Giattas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anagha","family":"Loharikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafrossa","family":"Lyimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.04.025_b0005","unstructured":"Bruni L, Albero G, Serrano B, Mena M, Gomez D, Munoz J, et al. Human Papillomavirus and Related Diseases in Tanzania. Summary Report. <http:\/\/www.hpvcentre.net\/statistics\/reports\/TZA.pdf?t=1544735268334 >; (2018) [accessed 2018 Dec 10]."},{"key":"10.1016\/j.vaccine.2021.04.025_b0010","unstructured":"International Agency for Research on Cancer. Cervix uteri. <https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/23-Cervix-uteri-fact-sheet.pdf >; (2018) [accessed 20 Nov 2019]."},{"key":"10.1016\/j.vaccine.2021.04.025_b0015","unstructured":"International Agency for Research on Cancer. Cancer Fact Sheets: Cervical Cancer. <http:\/\/gco.iarc.fr\/today\/data\/pdf\/fact-sheets\/cancers\/cancer-fact-sheets-16.pdf >; (2012) [accessed 20 Nov 2019]."},{"key":"10.1016\/j.vaccine.2021.04.025_b0020","unstructured":"International Agency for Research on Cancer. Tanzania, United Republic of Fact Sheet. <https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/834-tanzania-united-republic-of-fact-sheets.pdf >; (2018) [accessed 2018 Dec 14]."},{"key":"10.1016\/j.vaccine.2021.04.025_b0025","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3390\/vaccines3020408","article-title":"Gavi HPV Programs: Application to Implementation","volume":"3","author":"Hanson","year":"2015","journal-title":"Vaccines."},{"key":"10.1016\/j.vaccine.2021.04.025_b0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pvr.2017.06.003","article-title":"What works for human papillomavirus vaccine introduction in low and middle-income countries?","volume":"4","author":"Howard","year":"2017","journal-title":"Papillomavirus research (Amsterdam, Netherlands)."},{"key":"10.1016\/j.vaccine.2021.04.025_b0035","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1080\/21645515.2016.1178433","article-title":"The value of demonstration projects for new interventions: The case of human papillomavirus vaccine introduction in low- and middle-income countries","volume":"12","author":"Howard","year":"2016","journal-title":"Human vaccines & immunotherapeutics."},{"key":"10.1016\/j.vaccine.2021.04.025_b0040","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.pvr.2017.09.001","article-title":"Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007\u20132016","volume":"4","author":"Gallagher","year":"2017","journal-title":"Papillomavirus research (Amsterdam, Netherlands)."},{"key":"10.1016\/j.vaccine.2021.04.025_b0045","unstructured":"World Health Organization. Stakeholders' Meeting on the introduction of Human Papilloma Virus (HPV) Vaccine kicks off in the United Republic of Tanzania. <https:\/\/www.afro.who.int\/news\/stakeholders-meeting-introduction-human-papiilloma-virus-hpv-vaccine-kicks-united-republic >; [accessed 13 Apr 2020]."},{"key":"10.1016\/j.vaccine.2021.04.025_b0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12913-018-2976-2","article-title":"The impact of a human papillomavirus (HPV) vaccination campaign on routine primary health service provision and health workers in Tanzania: a controlled before and after study","volume":"18","author":"Gallagher","year":"2018","journal-title":"BMC health services research."},{"key":"10.1016\/j.vaccine.2021.04.025_b0055","unstructured":"Human Papillomavirus vaccination demonstration programme. Post-introduction evaluation report. Kilimanjaro region, Tanzania2014."},{"key":"10.1016\/j.vaccine.2021.04.025_b0060","unstructured":"United Republic of Tanzania. Application for Gavi new vaccine support. <https:\/\/www.gavi.org\/country\/tanzania\/documents\/ >; (2017) [accessed 2018 Dec 13]."},{"key":"10.1016\/j.vaccine.2021.04.025_b0065","unstructured":"Gavi. Decision Letter NVS Tanzania 2018. <https:\/\/www.gavi.org\/country\/tanzania\/documents\/dlpas\/decision-letter-nvs-tanzania-2018-(6)\/ >; (2018) [accessed 20 Nov 2019]."},{"key":"10.1016\/j.vaccine.2021.04.025_b0070","article-title":"Impact of the human papillomavirus (HPV) vaccine supply shortage on Tanzania's national HPV vaccine introduction","author":"Li","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.04.025_b0075","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/OLQ.0b013e31823b50ad","article-title":"Human papillomavirus prevalence and type distribution in 3603 HIV-positive and HIV-negative women in the general population of Tanzania: the PROTECT study","volume":"39","author":"Dartell","year":"2012","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2021.04.025_b0080","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/infdis\/jis407","article-title":"Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies","volume":"206","author":"Watson-Jones","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.025_b0085","unstructured":"Human papillomavirus vaccines: WHO position paper, May 2017. Releve epidemiologique hebdomadaire. 2017;92:241-68."},{"key":"10.1016\/j.vaccine.2021.04.025_b0090","unstructured":"World Health Organization. Considerations regarding consent in vaccinating children and adolescents between 6 and 17 years old. <https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/259418\/WHO-IVB-14.04-eng.pdf?sequence=1 >; (2014) [accessed 13 Apr 2020]."},{"key":"10.1016\/j.vaccine.2021.04.025_b0095","unstructured":"World Health Organization. Guide to introducing HPV vaccine into national immunization programmes. <https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/253123\/9789241549769-eng.pdf;jsessionid=C37D82864B0CA09FCACCEB26EE6EAE01?sequence=1 >; (2016) [accessed 13 Apr 2020]."},{"key":"10.1016\/j.vaccine.2021.04.025_b0100","unstructured":"Welfare TMoHaS. Guidelines for Surveillance of Adverse Events Following Immunization <https:\/\/www.tmda.go.tz\/uploads\/publications\/en1554376427-TANZANIA%20AEFI%20GUIDELINES%20%20.pdf >; (2014) [accessed 15 May 2020]."},{"key":"10.1016\/j.vaccine.2021.04.025_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177773","article-title":"Lessons learnt from human papillomavirus (HPV) vaccination in 45 low- and middle-income countries","volume":"12","author":"Gallagher","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.04.025_b0110","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/1471-2458-12-370","article-title":"Assessment of eight HPV vaccination programs implemented in lowest income countries","volume":"12","author":"Ladner","year":"2012","journal-title":"BMC public health."},{"key":"10.1016\/j.vaccine.2021.04.025_b0115","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2471\/BLT.11.089862","article-title":"Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries","volume":"89","author":"LaMontagne","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2021.04.025_b0120","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1186\/s12913-016-1824-5","article-title":"Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009\u20132014","volume":"16","author":"Ladner","year":"2016","journal-title":"BMC health services research."},{"key":"10.1016\/j.vaccine.2021.04.025_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045231","article-title":"Reasons for receiving or not receiving HPV vaccination in primary schoolgirls in Tanzania: a case control study","volume":"7","author":"Watson-Jones","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.04.025_b0130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.pcl.2015.08.004","article-title":"Global Delivery of Human Papillomavirus Vaccines","volume":"63","author":"Wigle","year":"2016","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.vaccine.2021.04.025_b0135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4314\/ahs.v15i1.5","article-title":"Feasibility of delivering HPV vaccine to girls aged 10 to 15 years in Uganda","volume":"15","author":"Mugisha","year":"2015","journal-title":"African health sciences."},{"key":"10.1016\/j.vaccine.2021.04.025_b0140","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1016\/j.vaccine.2012.06.025","article-title":"A qualitative study of HPV vaccine acceptability among health workers, teachers, parents, female pupils, and religious leaders in northwest Tanzania","volume":"30","author":"Remes","year":"2012","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.04.025_b0145","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1186\/s12889-016-3517-8","article-title":"Social mobilisation, consent and acceptability: a review of human papillomavirus vaccination procedures in low and middle-income countries","volume":"16","author":"Kabakama","year":"2016","journal-title":"BMC public health."},{"key":"10.1016\/j.vaccine.2021.04.025_b0150","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1016\/j.vaccine.2017.05.071","article-title":"Safety and perception: What are the greatest enemies of HPV vaccination programmes?","volume":"36","author":"Bonanni","year":"2018","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.04.025_b0155","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s40265-018-0975-6","article-title":"Human Papillomavirus Vaccines: Successes and Future Challenges","volume":"78","author":"Perez","year":"2018","journal-title":"Drugs."},{"key":"10.1016\/j.vaccine.2021.04.025_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090912","article-title":"Knowledge and awareness of HPV vaccine and acceptability to vaccinate in sub-Saharan Africa: a systematic review","volume":"9","author":"Perlman","year":"2014","journal-title":"PLoS ONE"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21004722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21004722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:09:10Z","timestamp":1759403350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21004722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":32,"alternative-id":["S0264410X21004722"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.04.025","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"National introduction of human papillomavirus (HPV) vaccine in Tanzania: Programmatic decision-making and implementation","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}